| 1 |
Treatment Response of Patients with Erythrodermic Psoriasis after Switching to Guselkumab |
|
| | Cheng-Ying Chiang,Tsen-Fang Tsai | | | Dermatology and Therapy. 2021; | | | [Pubmed] [Google Scholar] [DOI] | | | 2 |
Secukinumab 2-weekly vs. 4-weekly dosing in plaque-type psoriasis |
|
| | T.-F. Tsai | | | British Journal of Dermatology. 2021; | | | [Pubmed] [Google Scholar] [DOI] | | | 3 |
Secukinumab in patients with psoriasis who have responded inadequately to tumour necrosis factor inhibitor treatment |
|
| | T.-F. Tsai | | | British Journal of Dermatology. 2020; | | | [Pubmed] [Google Scholar] [DOI] | | | 4 |
Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study |
|
| | K. Reich,A. Körber,U. Mrowietz,M. Sticherling,C. Sieder,J. Früh,T. Bachhuber | | | British Journal of Dermatology. 2020; | | | [Pubmed] [Google Scholar] [DOI] | |
|
